According to the Alzheimer Research Forum, TauRx, a company based in Singapore, recently announced plans to conduct a phase three clinical trial for a drug called LMTX. LMTX is an updated version of a drug previously trialed called Rember that had been tested in 2008 with some positive results.
LMTX is slated to be tested on people with behavioral-variant frontotemporal dementia (bvFTD) with enrollment possibly beginning in November or December of this year. This type of frontotemporal dementia has historically been referred to as Pick's disease and affects between 50,000 to 60,000 Americans. The age of onset for bvFTD is generally younger than Alzheimer's and symptoms include behavioral and cognitive changes.
Two other phase three trials on LMTX are planned for testing in individuals with Alzheimer's, one targeting mild to moderate Alzheimer's lasting 12 months and one for those with mild Alzheimer's lasting 18 months.
More Information on Clinical Trials
Have you or a loved one participated in a clinical trial? If so, feel free to comment on your experience or share your thoughts.